Seres Therapeutics, Inc. Payments for Restructuring
Seres Therapeutics, Inc. (MCRB) reported Payments for Restructuring of $193.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2022-03-01
- Seres Therapeutics, Inc. payments for restructuring for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. payments for restructuring for the quarter ending 2020-03-31 was $192.00K, a 68.42% decline year-over-year.
- Seres Therapeutics, Inc. payments for restructuring for the quarter ending 2019-12-31 was $198.00K.
- Seres Therapeutics, Inc. payments for restructuring for the quarter ending 2019-09-30 was $206.00K.
- Seres Therapeutics, Inc. payments for restructuring for fiscal 2020 was $193.00K, a 85.14% decline from fiscal 2019.
- Seres Therapeutics, Inc. payments for restructuring for fiscal 2019 was $1.30M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2020-12-31 | $193.00K 10-K · filed 2022-03-01 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | $192.00K 10-Q · filed 2020-07-28 | $390.00K derived: sum of 3 quarters · filed 2022-03-01 | $596.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $192.00K 10-Q · filed 2020-05-07 | $390.00K derived: sum of 2 quarters · filed 2022-03-01 | $596.00K derived: sum of 3 quarters · filed 2022-03-01 | $882.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $198.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $404.00K derived: sum of 2 quarters · filed 2022-03-01 | $690.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.30M 10-K · filed 2022-03-01 |
| 2019-09-30 | $206.00K 10-Q · filed 2020-11-09 | $492.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.10M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $286.00K 10-Q · filed 2019-08-06 | $894.00K 10-Q · filed 2020-07-28 | ||
| 2019-03-31 | $608.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |